[1]王娟,刘鑫,席稳燕.HMMR-AS1 在子宫内膜癌化疗耐药中的作用[J].现代检验医学杂志,2020,35(05):45-50.[doi:10.3969/j.issn.1671-7414.2020.05.012]
　WANG Juan,LIU Xin,XI Wen-yan.Effect of HMMR-AS1 on the Chemotherapy-Resistance of Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2020,35(05):45-50.[doi:10.3969/j.issn.1671-7414.2020.05.012]
点击复制

HMMR-AS1 在子宫内膜癌化疗耐药中的作用()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第35卷
期数:
2020年05期
页码:
45-50
栏目:
论著
出版日期:
2020-11-01

文章信息/Info

Title:
Effect of HMMR-AS1 on the Chemotherapy-Resistance of Endometrial Cancer
文章编号:
1671-7414（2020）05-045-06
作者:
王娟1; 刘鑫1; 席稳燕2
1. 西安大兴医院妇产科, 西安 710016；2 西安交通大学第二附属医院妇科 , 西安710004
Author(s):
WANG Juan1;  LIU Xin1;  XI Wen-yan2
1.Department of Obstetrics and Gynecology, Daxing Hospital, Xi’an 710016, China；2.Department of Gynecology, the Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, China
关键词:
子宫内膜癌; 化疗; 耐药; 透明质酸介导的运动受体-AS1
分类号:
R737.33；R730.43
DOI:
10.3969/j.issn.1671-7414.2020.05.012
文献标志码:
A
摘要:
目的　探讨透明质酸介导的运动受体（hyaluronan mediated motility receptor， HMMR）-AS1 在子宫内膜癌 化疗耐药中的作用。方法　通过实时荧光定量PCR 法测定80 例子宫内膜癌肿瘤组织及其对照组织中HMMR-AS1 及 HMMR 的相对表达量；通过CCK-8 法测定异常表达的HMMR-AS1 对子宫内膜癌细胞增殖及化疗耐药的影响；通过 western blot 实验测定异常表达的HMMR-AS1 下游HMMR 蛋白质的变化。结果　HMMR-AS1 在子宫内膜癌中高表 达(P<0.01)，HMMR 在子宫内膜癌中亦表达上调(P<0.01)，且与HMMR-AS1 呈正相关(r2=0.7635, P<0.01)；过表达 HMMR-AS1 促进子宫内膜癌细胞增殖(P<0.01)，降低子宫内膜癌对化疗药物顺铂(P<0.01) 及5-FU(P<0.01) 的敏感性， 促进HMMR 蛋白质表达增加(P<0.01)。结论　HMMR-AS1 在子宫内膜癌中高表达，并促进子宫内膜癌细胞对化疗耐药。
Abstract:
Objective　To explore the effect of HMMR-AS1 on the chemotherapy-resistance of endometrial cancer. Methods　 The relative expression levels of HMMR-AS1 and HMMR in tumor tissues and control tissues of 80 cases of endometrial carcinoma were measured by real-time fluorescence quantitative PCR. The effect of HMMR-AS1 with abnormal expression on endometrial cancer cell proliferation and chemotherapy resistance was determined by CCK-8 assay. The changes of HMMRAS1 downstream HMMR protein with abnormal expression were determined by western blot. Results　HMMR-AS1 was highly expressed in endometrial cancer (P<0.01), and it was also up-regulated in endometrial cancer (P<0.01), and was positively correlated with HMMR-AS1 (r2=0.7635, P<0.01). Overexpression of HMMR-AS1 promoted the proliferation of endometrial cancer cells (P<0.01), decreased the sensitivity of endometrial cancer to chemotherapy drugs cisplatin (P<0.01) and 5-FU (P<0.01), and increased the expression of HMMR protein (P<0.01). Conclusion　HMMR-AS1 was upregulated in endometrial cancer and regulate the chemotherapy-resistance of endometrial cancer.

参考文献/References:

[1] 陈慧, 周思园, 孙振球. 常见妇科三大恶性肿瘤的 流行及疾病负担研究现状[J]. 中国现代医学杂志, 2015, 25(6):108-112. CHEN Hui, ZHOU Siyuan, SUN Zhenqiu. The prevalence and disease burden of three common gynecological malignancies[J]. China Journal of Modern Medicine, 2015, 25(6):108-112.
[2] 郑荣寿, 孙可欣, 张思维, 等. 2015 年中国恶性肿瘤 流行情况分析[J]. 中华肿瘤杂志, 2019,41(1):19-28. ZHENG Rongshou, SUN Kexin, ZHANG Siwei, et al. Report of cancer epidemiology in China, 2015[J]. Chin J Oncol, 2019,41(1):19-28.
[3] 陈万青, 李贺, 孙可欣, 等. 2014 年中国恶性肿瘤发 病和死亡分析[J]. 中华肿瘤杂志, 2018,40(1):5-13. CHEN Wanqing, LI He, SUN Kexin, et al. Report of cancer incidence and mortality in China, 2014[J]. Chin J Oncol, 2018,40(1):5-13.
[4] 陈万青, 郑荣寿, 张思维, 等. 2013 年中国老年人 群恶性肿瘤发病和死亡分析[J]. 中华肿瘤杂志, 2017,39(1):60-66. CHEN Wanqing, ZHENG Rongshou, ZHANG Siwei, et al. Analysis of cancer incidence and mortality in elderly population in China, 2013[J]. Chin J Oncol, 2017,39(1):60-66.
[5] 余昌, 岳成山, 王会霞, 等. Ⅲ期子宫内膜癌患者调 强放疗联合化疗治疗的疗效及不良反应分析[J]. 实 用癌症杂志, 2019,34(1):145-147. YU Chang, YUE Chengshan, WANG Huixia, et al. Clinical efficacy and adverse reactions of patients with stage Ⅲ endometrial cancer with TP chemotherapy combined with intensity modulated radiation therapy[J]. The Practical Journal of Cancer, 2019,34(1):145-147.
[6] 邢永新. 化疗干预子宫内膜癌患者血清肿瘤标志物 及癌组织中hmga2 的表达及意义[J]. 中国老年学杂 志, 2019,39(2):289-291. XING Yongxin. Chemotherapy intervention of serum tumor markers and expression of HMGA2 in endometrial cancer patients and its significance[J]. Chinese Journal of Gerontology, 2019,39(2):289-291.
[7] 张守桃，施桂玲，金明杨，等. 子宫内膜癌治疗的 研究进展[J]. 右江医学, 2018,46(6):737-740. ZHANG Shoutao, SHI Guiling, JIN Mingyang, et al. Research progress of treatment of endometrial cancer[J]. Chinese Youjiang Medical Journal, 2018,46(6):737-740.
[8] SHEN Chingju, CHENG Yamin, WANG Chuilin. Lncrna PVT1 epigenetically silences miR-195 and modulates emt and chemoresistance in cervical cancer cells [J]. J Drug Target, 2017,25(7):637-644.
[9] 王栋, 金岚, 王今, 等. MALAT1 在结直肠癌组织细 胞中的表达及对化疗敏感性的影响[J]. 中国医药导 报, 2016,13(32):12-16. WANG Dong, JIN Lan, WANG Jin, et al. Expression of MALAT1 in colorectal cancer tissue cells and its influence for the chemotherapy sensitivity[J]. Chin Med Herald, 2016,13(32):12-16.
[10] LIU Wei, MA Jun, CHENG Yong, et al. HMMR antisense RNA 1, a novel long noncoding RNA, regulates the progression of basal-like breast cancer cells [J]. Breast Cancer Targets and Therapy, 2016,8(1):223-229.
[11] CHEN Lamei, MA Dongmei, LI Yuanyuan, et al. Effect of long non-coding RNA PVT1 on cell proliferation and migration in melanoma [J]. Int J Mol Med, 2018,41(3):1275-1282.
[12] 饶建, 林秀欣, 李春鸣. 晚期子宫内膜癌术后同期放 化疗与序贯放化疗的疗效对比[J]. 现代诊断与治疗, 2018,29(13):2029-2032. RAO Jian, LIN Xiuxin, LI Chunming. Evaluation of concurrent chemoradiotherapy and sequential chemoradio-therapy for advanced endometrial carcinoma[J]. Mod Diagn Treat, 2018,29(13):2029- 2032.
[13] SUNG H, SIEGEL R L, TORRE L A, et al. Global patterns in excess body weight and the associated cancer burden [J]. CA Cancer J Clin, 2018,69(2):88- 112.
[14] WHO. World health statistics 2017：monitoring health for the SDGS，sustainable development goals [M]. France: World Health Organization, 2017.
[15] 孟一凡， 齐元富. 阿帕替尼治疗晚期子宫内膜 癌患者报告1 例[J]. 世界最新医学信息文摘, 2019,19(16):251. MENG Yifan, QI Yuanfu. A case of advanced endometrial carcinoma treated with apatinib is reported[J]. World Latest Medicine Information, 2019,19(16):251.
[16] YU Jing, JIANG Lijuan, GAO Yutao, et al. LncRNA CCAT1 negatively regulates miR-181a-5p to promote endometrial carcinoma cell proliferation and migration [J]. Exp Ther Med, 2019,17(5):4259-4266.
[17] KONG Y, REN Z. Overexpression of lncRNA fer1l4 in endometrial carcinoma is associated with favorable survival outcome [J]. Eur Rev Med Pharmacol Sci, 2018,22(23):8113-8118.
[18] CHU Z P, DAI J, JIA L G, et al. Increased expression of long noncoding RNA HMMR-AS1 in epithelial ovarian cancer: An independent prognostic factor [J]. Eur Rev Med Pharmacol Sci, 2018,22(23):8145-8150.
[19] LI Junyang, Ji Xiangjun, WANG Handong. Targeting long noncoding RNA HMMR-AS1 suppresses and radiosensitizes glioblastoma [J]. Neoplasia, 2018,20(5):456-466.
[20] 王冉冉, 董珊珊, 龙瀛, 等. HMMR-AS1 介导EMT 在上皮性卵巢癌顺铂获得性耐药中的作用[J]. 肿瘤 药学, 2018,8(4):498-504. WANG Ranran, DONG Shanshan, LONG Ying, et al. HMMR-AS1 mediated EMT in acquired cisplatin resistance of epithelial ovarian cancer[J]. Anti-tumor Pharmacy, 2018,8(4):498-504.

相似文献/References:

[1]李 玲a,罗雅文a,何 霞a,等.子宫内膜癌患者BMI与血清HE4,CA125联合检测的诊断价值[J].现代检验医学杂志,2018,33(05):91.[doi:10.3969/j.issn.1671-7414.2018.05.024]
　LI Linga,LUO Ya-wena,HE Xiaa,et al.Diagnostic Value of Combined Detection of Body Mass Index and Serum HE4,CA125 in Patients with Endometrial Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(05):91.[doi:10.3969/j.issn.1671-7414.2018.05.024]
[2]李晓丽,胡陇娟.子宫内膜癌组织中长链非编码RNA ZEB1-AS1的表达与临床特征及对化疗药物耐药性研究[J].现代检验医学杂志,2019,34(04):35.[doi:10.3969/j.issn.1671-7414.2019.04.009]
　LI Xiao-li,HU Long-juan.Research on Expression and Clinical Characteristics of Long-Chain Non-Coding RNA ZEB1-AS1 in Endometrial Carcinoma and Resistance to Chemotherapy Drugs[J].Journal of Modern Laboratory Medicine,2019,34(05):35.[doi:10.3969/j.issn.1671-7414.2019.04.009]
[3]李功娟,张治洋,樊阳阳.FEZF1-AS1在子宫内膜癌中的表达及其与患者临床特征的相关性[J].现代检验医学杂志,2021,36(01):77.[doi:10.3969/j.issn.1671-7414.2021.01.020]
　LI Gong-juan,ZHANG Zhi-yang,FAN Yang-yang.Expression of FEZF1-AS1 in Endometrial Carcinoma and Its Correlation with Clinical Characteristics of Patients[J].Journal of Modern Laboratory Medicine,2021,36(05):77.[doi:10.3969/j.issn.1671-7414.2021.01.020]
[4]陈丽华,朱婕曼,刘玉凤,等.子宫内膜癌组织中血管紧张素~1-7及线粒体组装受体水平表达与临床病理特征的相关性[J].现代检验医学杂志,2021,36(02):24.[doi:doi:10.3969/j.issn.1671-7414.2021.02.006]
　CHEN Li-hua,ZHU Jie-man,LIU Yu-feng,et al.Correlation between the Expression of Angiotensin (1-7) and Mitochondrial Assembled Receptors and Clinicopathological Characteristics in Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2021,36(05):24.[doi:doi:10.3969/j.issn.1671-7414.2021.02.006]
[5]陈晓宇,曾庆维,陈红林,等.子宫内膜癌组织中miR-3188和mTOR表达量与预后的相关性研究[J].现代检验医学杂志,2021,36(06):17.[doi:10.3969/j.issn.1671-7414.2021.06.004]
　CHEN Xiao-yu,ZENG Qing-wei,CHEN Hong-lin,et al.Study on the Correlation between the Expression Levels of miR-3188 and mTOR in Endometrial Cancer and the Prognosis[J].Journal of Modern Laboratory Medicine,2021,36(05):17.[doi:10.3969/j.issn.1671-7414.2021.06.004]
[6]刘静雅,张海亮,李宝平,等.长链非编码 RNA SNHG1在子宫内膜癌中的表达及调控 PI3K/AKT信号通路的研究[J].现代检验医学杂志,2022,37(01):119.[doi:10.3969/j.issn.1671-7414.2022.01.024]
　LIU Jing-ya,ZHANG Hai-liang,LI Bao-ping,et al.Expression of Long Non-coding RNA SNHG1 in Endometrial Carcinoma and Its Regulation of PI3K/AKT Signaling Pathway[J].Journal of Modern Laboratory Medicine,2022,37(05):119.[doi:10.3969/j.issn.1671-7414.2022.01.024]
[7]彭 浩,张印星,谢 环.长链非编码RNA CDKN2BAS 在子宫内膜癌组织表达及其生物学功能研究[J].现代检验医学杂志,2023,38(03):92.[doi:10.3969/j.issn.1671-7414.2023.03.016]
　PENG Hao,ZHANG Yin-xing,XIE Huan.Expression and Biological Function of Long Non-coding RNA CDKN2BAS in Endometrial Carcinoma[J].Journal of Modern Laboratory Medicine,2023,38(05):92.[doi:10.3969/j.issn.1671-7414.2023.03.016]
[8]梁燕茹,郑 瑜,李 倩.子宫内膜癌患者术前血清apo AI 和Apelin 水平检测对预测淋巴脉管间隙浸润风险的价值研究[J].现代检验医学杂志,2023,38(05):53.[doi:10.3969/j.issn.1671-7414.2023.05.010]
　LIANG Yanru,ZHENG Yu,LI Qian.Value of Preoperative Serum Apo AI and Apelin Levels in Predicting the Risk of Lymph Node Vascular Space Infiltration in Patients with Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2023,38(05):53.[doi:10.3969/j.issn.1671-7414.2023.05.010]
[9]陆 瑞,郭红霞,吴苗苗,等.KIF18B 通过激活Wnt/β catenin 信号通路促进子宫内膜癌细胞增殖和转移的实验研究[J].现代检验医学杂志,2023,38(05):58.[doi:10.3969/j.issn.1671-7414.2023.05.011]
　LU Rui,GUO Hongxia,WU Miaomiao,et al.Experimental Study of KIF18B Promoting Endometrial Cancer Cell Proliferation and Metastasis by Activating Wnt/β-catenin Signaling Pathway[J].Journal of Modern Laboratory Medicine,2023,38(05):58.[doi:10.3969/j.issn.1671-7414.2023.05.011]
[10]柴 静,张家弘,李梦雪.子宫内膜癌组织中TMIGD2，TIGIT 的表达及其与临床病理特征的相关性研究[J].现代检验医学杂志,2023,38(06):87.[doi:10.3969/j.issn.1671-7414.2023.06.016]
　CHAI Jing,ZHANG Jiahong,LI Mengxue.Expression of TMIGD2 and TIGIT in Endometrial Cancer Tissue and Their Correlation with Clinical Pathological Features[J].Journal of Modern Laboratory Medicine,2023,38(05):87.[doi:10.3969/j.issn.1671-7414.2023.06.016]

备注/Memo

备注/Memo:
作者简介：王娟（1985-），女, 本科，主治医师，研究方向：妇产科，E-mail：xiwangjuan@163.com。
通讯作者：刘鑫（1983-），女, 本科，主治医师，E-mail:397083371@qq.com。
更新日期/Last Update: 2020-10-30